Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.74 |
| ▸ | ESRRG | P62508 | 1/20 | 0.74 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.74 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.70 |
| ▸ | SPHK2 | Q9NRA0 | 8/20 | 0.70 |
| ▸ | SPHK1 | Q9NYA1 | 7/20 | 0.70 |
| ▸ | RRM1 | P23921 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | ECE2 | P0DPD6 | 1/20 | 0.57 |
| ▸ | ECE1 | P42892 | 1/20 | 0.57 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.57 |
| ▸ | IKBKB | O14920 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21211524 | 1.00 | ESR1 (0.74) | ESR1ESRRGESR2DNM1SPHK2 | |
| SCHEMBL2830968 | 0.88 | DNM1 (0.90) | ESR1ESRRGESR2DNM1SPHK2 | |
| SCHEMBL2830971 | 0.88 | DNM1 (0.90) | ESR1ESRRGESR2DNM1SPHK2 | |
| SCHEMBL13475421 | 0.88 | DNM1 (0.90) | ESR1ESRRGESR2DNM1SPHK2 | |
| SCHEMBL13569020 | 0.87 | ESR1 (0.89) | ESR1ESRRGESR2DNM1RRM1 | |
| SCHEMBL30513741 | 0.86 | ESRRG (0.82) | ESR1ESRRGESR2DNM1RRM1 | |
| SCHEMBL27178132 | 0.86 | ESRRG (0.82) | ESR1ESRRGESR2DNM1RRM1 | |
| SCHEMBL27178122 | 0.86 | ESRRG (0.82) | ESR1ESRRGESR2DNM1RRM1 | |
| SCHEMBL12937827 | 0.85 | ESRRG (1.00) | ESR1ESRRGESR2DNM1RRM1 | |
| SCHEMBL21211335 | 0.85 | MIF (0.67) | ESR1ESRRGESR2SPHK2SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421257-B2 | Compositions and methods for inhibiting group II intron RNA | YALE UNIVERSITY (US) | 2025-09-23 | — | — | US | disclosed |
| US-20240018169-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GROUP II INTRON RNA | UNIV YALE (US) | 2024-01-18 | — | — | US | disclosed |
| US-11739104-B2 | Compositions and methods for inhibiting group II intron RNA | YALE UNIVERSITY (US) | 2023-08-29 | — | — | US | disclosed |
| US-20210139512-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GROUP II INTRON RNA | YALE UNIVERSITY | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421257-B2 | Compositions and methods for inhibiting group II intron RNA | NSUN2, RBM22, RNGTT | ESR1 3894/4885ESRRG 3085/4885ESR2 2623/4885 |
| US-11739104-B2 | Compositions and methods for inhibiting group II intron RNA | NSUN2, RBM22, RNGTT | ESR1 3894/4885ESRRG 3085/4885ESR2 2623/4885 |
| US-20240018169-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GROUP II INTRON RNA | NSUN2, RBM22, RNGTT | ESR1 3894/4885ESRRG 3085/4885ESR2 2623/4885 |
| US-20210139512-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GROUP II INTRON RNA | NSUN2, RBM22, RNGTT | ESR1 3894/4885ESRRG 3085/4885ESR2 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.